The US government is funding the development of an effective treatment created by Israeli firm RedHill Biopharma for the ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

The new study shows how three antibodies (light blue, dark blue, and yellow) used in Inmazeb (REGN-EB3) bind to different regions of the Ebola virus glycoprotein (grey) to combat infection.

Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary ...

Regeneron also recently won FDA approval for Inmazeb, another antibody cocktail and the first-ever drug proved to be effective in treating Ebola. Those innovations have helped boost Regeneron’s ...

Currently, only Inmazeb, a combination of three monoclonal antibodies and Ebanga, a single monoclonal antibody, are FDA-approved to treat EBOV. Both are intravenously administered. According to ...